Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation
Authors:
- Kenichi ShikataKSKenichi Shikata
- Kosuke YozaiKYKosuke Yozai
- Shinichi OkadaSOShinichi Okada
- Daisuke OgawaDODaisuke Ogawa
- Hitomi UsuiHUHitomi Usui
- Jun WadaJWJun Wada
- Yasushi ShikataYSYasushi Shikata
- Hirofumi MakinoHMHirofumi Makino
- 1 April 2007
- journal article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 292 (4) , F1141-F1150
Abstract
Thiazolidinedione (TZD), a ligand for peroxisome proliferator-activated receptor-γ (PPAR-γ), exerts anti-inflammatory effects independently of the insulin-sensitizing effect. In the present study, we tested the hypothesis that TZD prevents the progression of diabetic nephropathy by modulating the inflammatory process. Five-week-old Sprague-Dawley rats were divided into three groups: 1) nondiabetic control rats (non-DM), 2) diabetic rats (DM), and 3) diabetic rats treated with pioglitazone (DM+pio). Diabetes was induced by injection with streptozotocin (STZ). The DM+pio group received 0.0002% pioglitazone mixed in chow for 8 wk after induction of diabetes. Blood glucose and HbA1c were elevated in diabetic rats but did not change by treatment with pioglitazone. Pioglitazone reduced urinary albumin excretion and glomerular hypertrophy, suppressed the expression of transforming growth factor (TGF)-β, type IV collagen, and ICAM-1, and infiltration of macrophages in the kidneys of diabetic rats. Furthermore, renal NF-κB activity was increased in diabetic rats and reduced by pioglitazone. PPAR-γ was expressed in glomerular endothelial cells in the diabetic kidney and in cultured glomerular endothelial cells. High-glucose conditions increased the expression of ICAM-1 and the activation of NF-κB in cultured glomerular endothelial cells. These changes were reduced by pioglitazone, ciglitazone, and pyrrolidine dithiocarbamate, an inhibitor of NF-κB. However, pioglitazone did not show the changes in the presence of PPAR-γ antagonist GW9662. Our results suggest that the preventive effects of pioglitazone may be mediated by its anti-inflammatory actions, including inhibition of NF-κB activation, ICAM-1 expression, and macrophage infiltration in the diabetic kidney.Keywords
This publication has 44 references indexed in Scilit:
- Differential effects of peroxisome proliferator activated receptor-γ (PPARγ) ligands in proximal tubular cells: Thiazolidinediones are partial PPARγ agonistsKidney International, 2004
- Involvement of NF-κB in High Glucose-induced Alteration of a-methyl-D-glucopyranoside (α-MG) Uptake in Renal Proximal Tubule CellsCellular Physiology and Biochemistry, 2003
- Nuclear Factor- B Suppressive and Inhibitor- B Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action?The Journal of Clinical Endocrinology & Metabolism, 2001
- Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in ratsKidney International, 2001
- Control of Vascular Cell Proliferation and Migration by PPAR-γDiabetes Care, 2001
- Transcription factor-κB (NF-κB) and renal diseaseKidney International, 2001
- Insufficient Glycemic Control Increases Nuclear Factor-κB Binding Activity in Peripheral Blood Mononuclear Cells Isolated From Patients With Type 1 DiabetesDiabetes Care, 1998
- Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.Journal of Clinical Investigation, 1998
- Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats.Journal of Clinical Investigation, 1997
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993